Idiopathic Pulmonary Fibrosis (IPF)
52
16
20
17
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
3.8%
2 terminated out of 52 trials
89.5%
+3.0% vs benchmark
8%
4 trials in Phase 3/4
18%
3 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (52)
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
IPF Longitudinal Natural History Study
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF
Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial
Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial
Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Expand Pulmonary Rehabilitation to Other Chronic Respiratory Diseases Than COPD
The relatıonshıp Between Upper Extremity Exercise Test and Exercise Capacity ın patıents wıth Idiopathic Pulmonary Fibrosis
Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis
Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell Therapy
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
SB17170 Phase 2 Trial in IPF Patients
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis